Aptahem

Aptahem P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Aptahem (APTA.SL) as of Oct 15, 2026 is -1.74. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -1.35 — a change of 29.03% (lower).

P/FCF

-1.74

YoY

29.03%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Aptahem is 2024 -1.74 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Aptahem was 2023 -1.35 . It decreases by 29.03% lower compared to the previous year.

The Aptahem P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2017
-2.07 SEK
Jan 1, 2018
-1.90 SEK
Jan 1, 2019
-1.64 SEK
Jan 1, 2020
-1.57 SEK
Jan 1, 2021
-0.83 SEK
Jan 1, 2022
-0.74 SEK
Jan 1, 2023
-1.35 SEK
Jan 1, 2024
-1.74 SEK
The Aptahem P/FCF history
YEARP/FCFYoY
-1.74+29.03%
-1.35+82.08%
-0.74-10.62%
-0.83-47.16%
-1.57-4.73%
-1.64-13.54%
-1.90-7.90%
-2.07-38.93%
-3.38-37.90%
-5.45—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptahem Stock analysis

What does Aptahem do? Aptahem AB is a biotechnology company based in Malmö, Sweden, operating within the healthcare sector. The company focuses on developing drug candidates aimed at treating and preventing diseases caused by blood vessel blockages due to blood clots, including conditions such as deep vein thrombosis, stroke, and heart failure. Aptahem AB went public through an IPO on April 17, 2015, and is listed under the ticker APTA.SL with ISIN SE0022447173. The company's headquarters are located in Malmö, a city in the Skåne region of Sweden. While the source material mentions a founding year of 2014, this detail is not confirmed by the provided facts, so it is omitted. Aptahem AB's website, aptahem.com, serves as the primary online resource for information about the company's activities and developments. The company operates in the biotechnology industry, specializing in therapeutic solutions for cardiovascular and related conditions. As a publicly traded entity, Aptahem AB is subject to the regulatory requirements of the Swedish financial market. The firm's strategic focus lies in addressing unmet medical needs through innovative drug development, targeting conditions that significantly impact patient outcomes and healthcare systems. The company's operations are centered in Malmö, reflecting its commitment to contributing to the biotechnology ecosystem in southern Sweden. Aptahem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptahem stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Aptahem is -1.74 in 2024.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Aptahem changed from -1.35 to -1.74, representing a 29.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Aptahem since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Aptahem with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Aptahem

All Key Metrics — Aptahem